Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Market News
Which ASX shares are leading the way on the ASX 300 today?
Earnings Results
Mesoblast (ASX:MSB) share price slides 10% following FY21 earnings
Share Market News
Why the Mesoblast (ASX:MSB) share price is edging higher on Tuesday
Share Market News
Why Emerge Gaming, Imugene, Mesoblast, & Nick Scali shares are dropping
Share Gainers
Why the Mesoblast (ASX:MSB) share price is dropping on Friday
Share Market News
These are the 10 most shorted ASX shares
Share Market News
ASX 200 Weekly Wrap: ASX shakes off lockdowns to rise higher
Share Fallers
These were the worst performing ASX 200 shares last week
Share Market News
Here's why the Mesoblast (ASX:MSB) share price is sinking today
Healthcare Shares
3 ASX healthcare shares with big news coming
Healthcare Shares
5 worst-performing ASX 200 healthcare shares of FY21
Healthcare Shares
Mesoblast (ASX:MSB) share price surges 5% in early trade today
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
